Search

The purposes of this study were to develop an automated process for radiologists to obtain clinical follow-up on radiology reports via HIPAA-compliant e-mail and to determine what follow-up data were collected and whether they were relevant to the radiology reports.The algorithm generated high-yield follow-up data for radiologists that may improve patient care by facilitating radiologist engagement and self-assessment.

The purpose of this study is to determine the interobserver agreement of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) for diagnosing prostate cancer using in-bore MRI-guided prostate biopsy as the reference standard.Fifty-nine patients underwent in-bore MRI-guided prostate biopsy between January 21, 2010, and August 21, 2013, and underwent diagnostic multiparametric MRI 6 months or less before biopsy. A single index lesion per patient was selected after retrospective review of MR images. Three fellowship-trained abdominal radiologists (with 1-11 years' experience) blinded to clinical information interpreted all studies according to PI-RADSv2. Interobserver agreement was assessed using Cohen kappa statistics.Thirty-eight lesions were in the peripheral zone and 21 were in the transition zone. Cancer was diagnosed in 26 patients (44%). Overall PI-RADS scores were higher for all biopsy-positive lesions (mean ± SD, 3.9 ± 1.1) than for biopsy-negative lesions (3.1 ± 1.0; p0.0001) and for clinically significant lesions (4.2 ± 1.0) than for clinically insignificant lesions (3.1 ± 1.0; p0.0001). Overall suspicion score interobserver agreement was moderate (κ = 0.45). There was moderate interobserver agreement among overall PI-RADS scores in the peripheral zone (κ = 0.46) and fair agreement in the transition zone (κ = 0.36).PI-RADSv2 scores were higher in the biopsy-positive group. PI-RADSv2 showed moderate interobserver agreement among abdominal radiologists with no prior experience using the scoring system.

The objective of our study was to determine whether morphologic features of adrenal masses detected at initial contrast-enhanced MDCT can differentiate benign from malignant disease.Two hundred eleven adrenal masses (1-4 cm) detected during standard contrast-enhanced MDCT with a proven final diagnosis were retrospectively identified in 188 patients through a computer search of CT, PET/CT, and pathology reports. Three authors blinded to the diagnoses independently reviewed the contrast-enhanced MDCT images of the adrenal masses and evaluated their morphologic features: lesion margin (smooth, lobulated, or irregular), density (homogeneous or heterogeneous), and additional features of central low density and enhancing rim. Using these criteria, the readers categorized each mass as probably benign, indeterminate, or suspicious.There were 171 (81%) benign and 40 (19%) malignant adrenal masses. All malignant masses were metastases diagnosed in patients with known extraadrenal malignancy. For individual morphologic features in diagnosing malignancy, irregular margins had 30-33% sensitivity and 95-96% specificity and an enhancing rim had 5-13% sensitivity and 98-99% specificity. None of the imaging features was reliable in predicting benignity. When an adrenal mass was deemed suspicious by a reader, the sensitivities for malignancy ranged from 54% to 74% and specificities from 96% to 97%. Notably, no malignant lesions occurred in patients without a known history of cancer.At routine contrast-enhanced MDCT, adrenal masses with irregular margins or a thick enhancing rim are likely to be malignant. Smooth margins and homogeneous density can be seen in both benign and malignant adrenal masses and are insufficient for characterization.

The purpose of this study is to examine the utility of appendix MRI in evaluation of pediatric patients with right lower quadrant pain and inconclusive appendix sonography findings.A search of the radiology electronic database was performed for all appendix MRI examinations performed of pediatric patients within 24 hours after inconclusive appendix sonography from December 1, 2009, through April 26, 2012. Sixty patients underwent appendix MRI within 24 hours of inconclusive sonography and represented the study cohort. MRI examinations were reviewed independently by two radiologists blinded to the diagnosis and were graded as "positive," "negative," or "indeterminate" for acute appendicitis. The final diagnosis was established by review of the surgical and pathology reports and patients' electronic medical records.Ten of 60 patients (17%) had acute appendicitis. Both readers graded the same 12 examinations as positive and the same 48 examinations as negative for acute appendicitis, with a kappa value of 1.00 (expected agreement, 0.695). No MRI examination was interpreted as indeterminate. The sensitivity and specificity of MRI for acute appendicitis in children with inconclusive appendix ultrasound findings were 100% (95% CI, 0.72-1.00) and 96% (95% CI, 0.87-0.98), respectively. The positive predictive value for the examination was 83%, the negative predictive value was 100%, and overall test accuracy was 97%.Our study shows that MRI has a sensitivity of 100% and specificity of 96% for appendicitis in pediatric patients after inconclusive appendix sonography. We think that MRI may supplant CT as the secondary modality to follow inconclusive appendix sonography.

The purpose of this study is to describe the prevalence and the characteristics of clinically important incidental extraurinary findings detected at MDCT urography performed for hematuria.A computer search of CT reports using the term "hematuria" identified 1209 reports of patients who had undergone MDCT urography. The results were retrospectively reviewed to determine unsuspected extraurinary findings that are clinically important or potentially important, warranting further imaging studies or medical or surgical intervention. We further categorized these important findings as acute (i.e., requiring immediate medical attention) or nonacute (i.e., requiring further evaluation in a nonurgent manner). By use of our electronic medical records, these findings were correlated to histologic diagnosis, further imaging evaluation, and clinical information.In 82 of 1209 patients (6.8%), 85 clinically important incidental extraurinary findings were identified. Follow-up evaluation was available for 43 of 85 (50.6%) findings by histologic diagnosis (n = 9), imaging evaluation (n = 31), or clinical information (n = 3). There were 11 (0.9%) examinations with acute findings, of which acute inflammation of the gastrointestinal tract and pancreaticobiliary system were the most common. Seventy-two (5.9%) examinations revealed 74 nonacute but important findings. Lung nodules were the most prevalent, followed by intraabdominal aneurysms and cystic ovarian masses. There were five (0.4%) histologically proven malignant neoplasms.The prevalence of clinically important incidental extraurinary findings at MDCT urography performed for hematuria was 6.8%.

The objective of our study was to report the incidence of multiple sporadic primary renal cell carcinomas (RCCs) in patients referred for radiofrequency ablation (RFA).A retrospective search identified 162 patients (104 men and 58 women; mean age, 74 years) without a history of von Hippel-Lindau disease with a total of 175 tumors treated with RFA for biopsy-proven primary renal malignancies at our institution from 1998 to 2009. Three groups of patients with multiple RCCs were identified: patients with a history of nephrectomy for RCC who had been referred for RFA of a new renal tumor, patients who presented with multiple renal tumors at the time of referral for RFA, and patients who were shown to have developed a new renal tumor on follow-up imaging after RFA.Twenty-eight patients (17%) had multiple biopsy-proven RCCs. Eighteen patients (11%) had undergone prior nephrectomy for surgically proven RCC. The mean interval between prior nephrectomy and RFA referral was 122 months (range, 12-456 months). Seven patients (4%) without a history of nephrectomy presented with two biopsy-proven RCCs at RFA referral. Three patients (2%) who had not undergone nephrectomy and had a solitary RCC at the time of RFA had developed a new biopsy-proven RCC separate from the original treatment site on follow-up imaging after RFA. The mean time to diagnosis from the initial RFA treatment was 52 months (range, 25-89 months).Imaging surveillance of patients referred for renal RFA may be important not only to assess treatment success but also to detect new RCCs.

The objective of our study was to evaluate the accuracy of dynamic contrast-enhanced 4D MDCT in the preoperative identification of parathyroid adenomas in patients with primary hyperparathyroidism (PHPT) and a history of failed surgery or unsuccessful localization on standard imaging.Thirty-four patients with PHPT underwent 4D CT. Retrospective blinded review of the 4D CT examinations was performed by three radiologists for the presence and location of a suspected parathyroid adenoma or adenomas. At the time of the study, 25 patients underwent surgical exploration after 4D CT. Twenty patients had solitary parathyroid adenomas, two patients had two adenomas resected, two patients did not have an adenoma, and one patient had mild four-gland hyperplasia. One patient did not have PHPT on repeat serum biochemistry. Surgical and pathology reports, adenoma enhancement, and biochemical and clinical follow-up were reviewed. Data were compared with 4D CT interpretations and interobserver reliability was calculated.The mean sensitivity and specificity of the three readers for the precise CT localization of adenomas was 82% (range, 79-88%) and 92% (range, 75-100%), respectively. Overall interobserver reliability was excellent (κ = 0.70; range, κ = 0.60-0.79). All adenomas resected at surgery showed a biochemical response and clinical response. The mean densities of the confirmed adenomas were 41, 128, 138, and 109 HU at 0, 30, 60, and 90 seconds, respectively. Level II lymph nodes identified in 10 patients showed significantly less enhancement at 30 (p = 0.0001) and 60 (p = 0.006) seconds compared with surgically proven adenomas.Occult parathyroid adenoma shows characteristic early enhancement. In this subset of patients, 4D CT may improve surgical outcomes and decrease morbidity.

Received November 14, 2008; accepted after revision November 4, 2009. 1Department of Diagnostic Imaging, The Warren Alpert Medical School of Brown University, Women and Infants Hospital, Rhode Island Hospital, 593 Eddy St., Providence, RI 02903. Address correspondence to C. A. Woodfield (courtneywoodfield@yahoo.com). 2Present address: Department of Radiology, University of California at San Diego, San Diego, CA. AJR 2010;194:S42–S45 0361–803X/10/1946–S42 © American Roentgen Ray Society ABSTRACT The educational objectives for this self-assessment module are for the participant to exercise, self-assess, and improve his or her understanding of the imaging evaluation of abdominal pain during pregnancy.

The purpose of this study is to describe the CT appearance of thoracic neoplasms after treatment with radiofrequency ablation (RFA).Thirty-two thoracic neoplasms in 26 patients had pulmonary RFA and imaging follow-up. Fourteen neoplasms were primary lung cancer and 18 were metastases. The mean pretreatment neoplasm size was 3.1 cm (range, 1.0-7.0 cm), and the average number of neoplasms treated per patient was 1.2 (range, 1-3). The mean follow-up was 10.1 months (range, 1-30 months). Imaging findings on CT were evaluated by three radiologists and documented by consensus.The most common finding immediately after treatment was peripheral ground-glass opacity surrounding the treated neoplasm, seen in 27 of 32 tumors (84%). This rapidly resolved in all but one patient by the end of the first month. Cavitation was seen in 10 of 32 tumors (31%) on follow-up CT and was most common in neoplasms in the inner two thirds of the lung and adjacent to a segmental bronchus. Sixty percent of the cavitations decreased in size on follow-up scans. Ten of 32 tumors (31%) that did not develop cavitation developed bubble lucencies on follow-up CT. Pleural thickening was found in 12 of 22 (55%) parenchymal neoplasms, and linear opacifications were seen between the treated lesion and adjacent pleura in 14 of 22 parenchymal tumors (64%). Pleural effusions were seen in four patients (15%). Fourteen of 22 tumors (64%) with follow-up imaging at 1 month enlarged from pretreatment CT scans. At 3 and 6 months after RFA, the majority remained stable in size.Peripheral ground-glass opacity, cavitation, bubble lucencies, and pleural changes are common findings on CT after RFA. Many treated neoplasms increase in size from baseline on 1- to 3-month follow-up CT scans and then remain stable thereafter. Enlargement of a treated tumor after 6 months is felt to represent local recurrence. Stability of a treated lesion beyond 6 months does not guarantee continued stability.

OBJECTIVE. The objective of our study was to describe our initial experience using percutaneous cryoablation for palliation of symptomatic extraabdominal metastases or recurrent soft-tissue tumors.CONCLUSION. Preliminary results suggest that percutaneous cryoablation may offer a minimally invasive alternative for relief of symptomatic metastatic disease in patients for whom conventional therapy failed.

The purpose of this study was to determine whether the addition of gadolinium-enhanced imaging to heavily T2-weighted MR imaging of the liver is valuable in differentiating hemangiomas from metastases. The T2 relaxation time was also included in our analysis.Fifty-one patients with 52 proven liver lesions (24 hemangiomas and 28 metastases) larger than 1 cm underwent MR imaging at 1.5 T with T2-weighted spin-echo (TR/TE, 3000/80, 160) and gadolinium chelate-enhanced dynamic T1-weighted gradient-recalled echo (80/2.6, 80) pulse sequences. Images were reviewed by observers who were unaware of the patients' clinical history; first, only T2-weighted images were reviewed and then T2-weighted plus dynamic images were reviewed together. The T2 relaxation times were calculated for each lesion. Diagnostic accuracy by each method was compared using receiver operating characteristic analysis.Mean T2 relaxation times were 76 +/- 26 msec for metastases and 133 +/- 25 msec for hemangiomas. The addition of dynamic scanning to the T2-weighted sequence made a statistically significant difference for only one observer (p = 0.03). However, it did not make a statistically significant contribution for either observer when compared with the T2 relaxation time. Although addition of the dynamic images resulted in correct diagnosis of six lesions, three lesions were misdiagnosed after having been correctly characterized on the T2-weighted images alone.When optimized T2-weighted images are obtained and the T2 relaxation time is calculated, routine use of gadolinium enhancement for differentiation of hemangiomas from metastases is unnecessary although dynamic scanning is valuable in selected cases.

The purpose of this study was to determine whether an in-hospital transportable CT scanner can provide diagnostic brain images and to compare the quality of these images with those from a conventional fixed-platform CT scanner.Twenty-seven patients with known or suspected intracranial pathology underwent imaging on a transportable scanner and a fixed-platform scanner within 1 hr of each other. Images from each CT examination were evaluated independently by two neuroradiologists who were unaware of patient history. Conspicuousness of intracranial pathology and normal anatomy were rated on a 5-point scale (1 point, optimal; 5 points, poor or not visualized). Statistical comparisons were made using nonparametric tests.Seven CT scans were interpreted as showing normal findings and 20 scans revealed intracranial pathology on both CT scanners. Image quality was higher on the fixed scanner (average rating, 2.42 points; SE = .12) than on the transportable scanner (average rating, 3.10 points; SE = .12) (p = .001). Depiction of the cerebellum, midbrain, and supratentorial gray-white matter was better on the fixed scanner (p.05). However, we found no significant differences in detection of intracranial pathology between scanners. Both radiologists found images from both scanners to be diagnostic in all 27 patients.Images of the brain on the transportable CT scanner were less clear than those on a fixed scanner. However, images from the transportable CT scanner were diagnostic in 27 consecutive patients. The implications of this finding are important for the provision of CT services for critically ill patients who cannot be transported to the radiology department.

OBJECTIVE: Portal venous gas has historically been associated with a poor prognosis. The clinical outcomes of 17 patients with portal venous gas detected by CT were reviewed. CONCLUSION: Portal venous gas seen on CT was associated with a 71% survival rate. Patients with a history of vascular surgery or bowel obstruction may have a higher mortality, and careful clinical evaluation is mandatory in this patient population.

The purpose of this study were to quantify abdominal vascular enhancement and to prove the feasibility of iron oxide-enhanced MR angiography in humans using three doses of superparamagnetic iron oxide agent AMI 227.Sixteen patients randomly received either 0.8, 1.1, or 1.7 mg Fe/kg of ultrasmall superparamagnetic iron oxide agent AMI 227. T1-weighted breath-hold gradient-echo images were obtained before and 45 min after i.v. administration of AMI 227. Signal intensity was measured in the aorta, the inferior vena cava, the portal vein, and muscle on unenhanced and contrast-enhanced images. Signal-to-noise ratios and enhancement [(SNR after contrast-SNR before contrast) / SNR before contrast] were calculated. Vessels were visually graded before and after administration of AMI 227.All vessels showed statistically significant enhancement 45 min. after administration of AMI 227 by both qualitative and quantitative measures (p.001). There was no significant increase in noise or signal intensity of muscle after contrast material was administered. The amount of enhancement was not statistically significantly different among the three doses.AMI 227, which is currently in phase III clinical trials, demonstrates significant vascular enhancement and may prove useful as an MR angiographic contrast agent.

The purpose of this study was to develop an algorithm using CT and chemical-shift MR imaging for the characterization of adrenal masses in patients with a primary cancer and no other evidence of metastatic disease.Thirty-three patients with 37 adrenal masses (19 metastases, 18 adenomas), all of whom had a known primary cancer, were studied with noncontrast CT and chemical-shift MR imaging (1.5 T). Lesion size and density in Hounsfield units (H) were determined by CT. Adrenal signal intensity normalized to that of spleen was used to calculate adrenal-spleen ratio (ASR), defined as the percentage of signal remaining in the opposed-phase image relative to the in-phase image. Lesions less than or equal to 0 H were classified as benign, lesions greater than 20 H were regarded as malignant, and lesions between 0 and 20 H were regarded as indeterminate. Diagnoses were confirmed by biopsy (for 19 lesions) or by follow-up imaging (for 18 lesions). An imaging algorithm was derived by determining the relative value of CT and MR imaging for diagnosing the lesions. The reimbursement rates for CT-guided biopsy and MR imaging of the abdomen were obtained from Medicare.All 13 lesions of 0 or less H were correctly classified as benign by CT. ASR was less than 70 in 10 of these 13. In another 13 lesions, H was greater than 20; all were malignant and all had an ASR greater than 80. Of 11 CT-indeterminate lesions, four of five adenomas had an ASR less than 70, and four of six metastases had an ASR greater than 80. Two malignant lesions had ASRs between 70 and 80 and were diagnosed by biopsy findings. One CT-indeterminate adenoma had an ASR of 84 and was diagnosed by biopsy findings. The reimbursement rate by Medicare is similar for CT-guided biopsy with pathologic interpretation and for MR imaging of the abdomen.An algorithm was developed for diagnosis of adrenal lesions that uses the density reading on noncontrast CT as the first step, with chemical-shift MR imaging for CT-indeterminate lesions. In this algorithm, lesions of 0 H or less may be regarded as benign and further work-up is not required. Lesions with a density greater than 20 H are likely malignant and should be biopsied when the result will influence management. For CT-indeterminate lesions, we recommend chemical-shift MR imaging. An ASR threshold of 70 indicates a benign lesion, and no further workup is required in these patients. Lesions with an ASR greater than 70 should have a biopsy performed, depending on the clinical situation. The above algorithm is cost-effective and reduces the number of biopsies required without reducing the sensitivity of detecting malignant lesions.

The purpose of this study was to describe the MR imaging characteristics of hepatic adenomas and to correlate these features with pathologic findings.Sixteen patients from four institutions who had 31 hepatocellular adenomas underwent MR imaging with T1- and T2-weighted pulse sequences at 1.5 T. Dynamic gadolinium-chelate-enhanced gradient-recalled-echo (GRE) MR imaging was done in eight patients with 15 lesions. Twenty-three lesions in 15 patients were confirmed by surgical excision. MR images were retrospectively reviewed by three experienced radiologists for signal intensity of lesions relative to liver, heterogeneity, contrast enhancement, and presence of signs of histopathologic correlates. These imaging findings were then compared with histopathologic findings.Nearly all (29 of 31 lesions) hepatocellular adenomas showed heterogeneous signal intensity on MR images. Most (19/31) were predominantly hyperintense on proton density- or T2-weighted images; the predominant signal intensity on T1-weighted images varied. Thirteen of 15 lesions showed early arterial enhancement relative to liver on dynamic GRE MR images. MR imaging was most successful in showing intratumoral hemorrhage (10 of 12 histopathologically proven lesions), large intratumoral vessels (five of five), fatty change (three of six), and peliosis (three of three cases). In two lesions, capsules (one of five) and central scars (one of three) were detected.Hepatocellular adenomas have a highly variable appearance on MR images because of their varied histologic appearances. Although no definitive MR imaging signal or structural characteristics can be identified, tumor heterogeneity, particularly when related to hemorrhage, and early arterial enhancement can suggest a diagnosis of hepatocellular adenoma in the proper patient population.

The purposes of this study were to evaluate the ability of chemical shift MR imaging to differentiate 1- to 5-cm adrenal adenomas from metastases and to compare subjective interpretation with several different quantitative measures.Forty-three patients with 46 proved adrenal lesions (28 adenomas and 18 metastases) had MR imaging with a gradient-echo breath-hold technique and echo time varied to obtain in-phase and out-of-phase images. Qualitative analysis of the MR images was done by three experienced observers, who reported their confidence in diagnosing the benignity versus the malignancy of the adrenal masses on the basis of signal loss on out-of-phase images. Quantitative analysis was performed by calculating the difference in signal intensity between in-phase and out-of-phase images by use of regions of interest (signal intensity index) and by use of adrenal-liver, adrenal-spleen, and adrenal-muscle signal intensity ratios. Results between quantitative and qualitative measures were compared by use of receiver operating characteristic (ROC) analysis.The mean signal intensity was significantly different between adenomas and metastases on out-of-phase images (64 versus 98) (p.0005) but not in-phase images (130 versus 122) (p = .47). The adrenal-spleen ratio discriminated between adenomas and metastases better than did the adrenal-liver ratio, the adrenal-muscle ratio, or the signal intensity index. No significant difference in interpretation among the three observers was evident (areas under the ROC curves, 0.93, 0.95, and 0.96). The performance of the observers was comparable to the results obtained with the adrenal-spleen ratio measurement (area under the ROC curve, 0.97).Experienced observers were able to differentiate adrenal adenomas from metastases just as well as quantitative measures. The adrenal-spleen ratio is the best quantitative means of distinguishing benign from malignant adrenal masses. Chemical shift MR imaging is a good but imperfect discriminator of adrenal adenomas.

OBJECTIVE. We sought to describe a multiinstitutional database created for tracking CT and sonographically guided interventional procedures.CONCLUSION. The database, created using commercially available software, has been placed on the secure hospital internal network for easy access from two institutions. More than 1,000 separate interventions have been added. The data may be queried and filtered for quality assurance and research purposes.